CoChat

Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening

Open access
Colas, Claire, Grewer, Christof, Otte, Nicholas James, Gameiro, Armanda, Albers, Thomas, Singh, Kurnvir, Shere, Helen, Bonomi, Massimiliano, Holst, Jeff, Schlessinger, Avner · 2015 · PLOS Computational Biology
Cited by 67

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane protein that transports neutral amino acids into cells in exchange for outward movement of intracellular amino acids. ASCT2 is highly expressed in peripheral tissues such as the lung and intestines where it contributes to the homeostasis of intracellular concentrations of neutral amino acids. ASCT2 also plays an important role in the development of a variety of cancers such as melanoma by transporting amino acid nutrients such as glutamine into the proliferating tumors. Therefore, ASCT2 is a key drug target with potentially great pharmacological importance. Here, we identify seven ASCT2 ligands by computational modeling and experimental testing. In particular, we construct homology models based on crystallographic structures of the aspartate transporter GltPh in two different conformations. Optimization of the models' binding sites for protein-ligand complementarity reveals new putative pockets that can be targeted via structure-based drug design. Virtual screening of drugs, metabolites, fragments-like, and lead-like molecules from the ZINC database, followed by experimental testing of 14 top hits with functional measurements using electrophysiological methods reveals seven ligands, including five activators and two inhibitors. For example, aminooxetane-3-carboxylate is a more efficient activator than any other known ASCT2 natural or unnatural substrate. Furthermore, two of the hits inhibited ASCT2 mediated glutamine uptake and proliferation of a melanoma cancer cell line. Our results improve our understanding of how substrate specificity is determined in amino acid transporters, as well as provide novel scaffolds for developing chemical tools targeting ASCT2, an emerging therapeutic target for cancer and neurological disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pcbi.1004477

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 53

  1. BC Fuchs, 2005, Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?, Semin Cancer Biol, 15, 254, 10.1016/j.semcancer.2005.04.005 · DOI · Paper page
  2. P Ren, 2015, ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation, J Pathol, 235, 90, 10.1002/path.4429 · DOI · Paper page
  3. M Hassanein, 2013, SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival, Clin Cancer Res, 19, 560, 10.1158/1078-0432.CCR-12-2334 · DOI · Paper page
  4. Q Wang, 2014, Targeting glutamine transport to suppress melanoma cell growth, Int J Cancer, 135, 1060, 10.1002/ijc.28749 · DOI · Paper page
  5. P Nicklin, 2009, Bidirectional transport of amino acids regulates mTOR and autophagy, Cell, 136, 521, 10.1016/j.cell.2008.11.044 · DOI · Paper page
  6. Q Wang, 2013, Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development, J Natl Cancer Inst, 105, 1463, 10.1093/jnci/djt241 · DOI · Paper page
  7. A Schlessinger, 2013, Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters, Curr Top Med Chem, 13, 843, 10.2174/1568026611313070007 · DOI
  8. D Yernool, 2004, Structure of a glutamate transporter homologue from Pyrococcus horikoshii, Nature, 431, 811, 10.1038/nature03018 · DOI · Paper page
  9. O Boudker, 2007, Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter, Nature, 445, 387, 10.1038/nature05455 · DOI · Paper page
  10. A Schlessinger, 2013, SLC Classification: An Update, Clin Pharmacol Ther, 94, 19, 10.1038/clpt.2013.73 · DOI · Paper page
  11. S Qu, 2008, Substrates and non-transportable analogues induce structural rearrangements at the extracellular entrance of the glial glutamate transporter GLT-1/EAAT2, J Biol Chem, 283, 26391, 10.1074/jbc.M802401200 · doi:10.1074/jbc.m802401200
  12. T Albers, 2012, Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs, Molecular Pharmacology, 81, 356, 10.1124/mol.111.075648 · DOI
  13. AJ Scopelliti, 2013, Molecular determinants for functional differences between alanine-serine-cysteine transporter 1 and other glutamate transporter family members, J Biol Chem, 288, 8250, 10.1074/jbc.M112.441022 · DOI
  14. ER Georgieva, 2013, Conformational ensemble of the sodium-coupled aspartate transporter, Nat Struct Mol Biol, 20, 215, 10.1038/nsmb.2494 · DOI
  15. S Stolzenberg, 2012, Structural intermediates in a model of the substrate translocation path of the bacterial glutamate transporter homologue GltPh, J Phys Chem B, 116, 5372, 10.1021/jp301726s · DOI
  16. TJ Crisman, 2009, Inward-facing conformation of glutamate transporters as revealed by their inverted-topology structural repeats, Proc Natl Acad Sci U S A, 106, 20752, 10.1073/pnas.0908570106 · DOI · Paper page
  17. O Jardetzky, 1966, Simple allosteric model for membrane pumps, Nature, 211, 969, 10.1038/211969a0 · DOI · Paper page
  18. N Reyes, 2009, Transport mechanism of a bacterial homologue of glutamate transporters, Nature, 462, 880, 10.1038/nature08616 · DOI · Paper page
  19. J Carlsson, 2011, Ligand discovery from a dopamine D3 receptor homology model and crystal structure, Nat Chem Biol, 7, 769, 10.1038/nchembio.662 · DOI · Paper page
  20. EG Geier, 2013, Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1, Proc Natl Acad Sci U S A, 110, 5480, 10.1073/pnas.1218165110 · DOI · Paper page
  21. A Schlessinger, 2011, Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET, Proc Natl Acad Sci U S A, 108, 15810, 10.1073/pnas.1106030108 · DOI · Paper page
  22. PM Ung, 2015, DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors, ACS Chem Biol, 10, 269, 10.1021/cb500696t · DOI
  23. A Sali, 1993, Comparative protein modelling by satisfaction of spatial restraints, J Mol Biol, 234, 779, 10.1006/jmbi.1993.1626 · DOI · Paper page
  24. GG Krivov, 2009, Improved prediction of protein side-chain conformations with SCWRL4, Proteins, 77, 778, 10.1002/prot.22488 · DOI · Paper page
  25. B Hess, 2008, GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation, Journal of Chemical Theory and Computation, 4, 435, 10.1021/ct700301q · DOI · Paper page
  26. H Fan, 2009, Molecular docking screens using comparative models of proteins, J Chem Inf Model, 49, 2512, 10.1021/ci9003706 · DOI · Paper page
  27. M Kanehisa, 2000, KEGG: kyoto encyclopedia of genes and genomes, Nucleic Acids Res, 28, 27, 10.1093/nar/28.1.27 · DOI · Paper page
  28. M Kanehisa, 2014, Data, information, knowledge and principle: back to metabolism in KEGG, Nucleic Acids Res, 42, D199, 10.1093/nar/gkt1076 · DOI · Paper page
  29. ID Kuntz, 1992, Structure-based strategies for drug design and discovery, Science, 257, 1078, 10.1126/science.257.5073.1078 · DOI · Paper page
  30. A Broer, 2000, Neutral amino acid transporter ASCT2 displays substrate-induced Na+ exchange and a substrate-gated anion conductance, Biochemical Journal, 346, 705, 10.1042/bj3460705 · doi:10.1042/bj3460705 · Paper page
  31. C Grewer, 2004, New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak, J Physiol, 557, 747, 10.1113/jphysiol.2004.062521 · DOI · Paper page
  32. C Grewer, 2004, New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak, The Journal of physiology, 557, 747, 10.1113/jphysiol.2004.062521 · DOI · Paper page
  33. N Watzke, 2001, The anion conductance of the glutamate transporter EAAC1 depends on the direction of glutamate transport, FEBS Lett, 503, 121, 10.1016/S0014-5793(01)02715-6 · doi:10.1016/s0014-5793(01)02715-6
  34. RJ Bridges, 2005, The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes, Pharmacol Ther, 107, 271, 10.1016/j.pharmthera.2005.01.002 · DOI
  35. CB Zander, 2013, Voltage-dependent processes in the electroneutral amino acid exchanger ASCT2, J Gen Physiol, 141, 659, 10.1085/jgp.201210948 · doi:10.1085/jgp.201210948
  36. K Muller, 2007, Fluorine in pharmaceuticals: looking beyond intuition, Science, 317, 1881, 10.1126/science.1131943 · DOI · Paper page
  37. MJ Zamek-Gliszczynski, 2012, Highlights from the international transporter consortium second workshop, Clinical pharmacology and therapeutics, 92, 553, 10.1038/clpt.2012.126 · DOI · Paper page
  38. K Traynor, 2013, Canagliflozin approved for type 2 diabetes, Am J Health Syst Pharm, 70, 834, 10.2146/news130035 · doi:10.2146/news130035
  39. J Pei, 2008, PROMALS3D: a tool for multiple protein sequence and structure alignments, Nucleic acids research, 36, 2295, 10.1093/nar/gkn072 · DOI · Paper page
  40. MY Shen, 2006, Statistical potential for assessment and prediction of protein structures, Protein Sci, 15, 2507, 10.1110/ps.062416606 · DOI · Paper page
  41. D Eramian, 2008, How well can the accuracy of comparative protein structure models be predicted?, Protein Sci, 17, 1881, 10.1110/ps.036061.108 · DOI · Paper page
  42. K Lindorff-Larsen, 2010, Improved side-chain torsion potentials for the Amber ff99SB protein force field, Proteins, 78, 1950, 10.1002/prot.22711 · DOI · Paper page
  43. B Hess, 2007, P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation, J Chem Theory Comput, 4, 116, 10.1021/ct700200b · DOI · Paper page
  44. RG Coleman, 2013, Ligand pose and orientational sampling in molecular docking, PLoS One, 8, e75992, 10.1371/journal.pone.0075992 · DOI · Paper page
  45. A Schlessinger, 2011, Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET, Proc Natl Acad Sci U S A, 108, 15810, 10.1073/pnas.1106030108 · DOI · Paper page
  46. A Schlessinger, 2012, High Selectivity of the gamma-Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach, Journal of Biological Chemistry, 287, 37745, 10.1074/jbc.M112.388157 · DOI
  47. R Kekuda, 1996, Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line, J Biol Chem, 271, 18657, 10.1074/jbc.271.31.18657 · DOI · Paper page
  48. 2010, The Universal Protein Resource (UniProt) in 2010, Nucleic Acids Res, 38, D142, 10.1093/nar/gkp846 · DOI · Paper page
  49. M McGann, 2011, FRED pose prediction and virtual screening accuracy, J Chem Inf Model, 51, 578, 10.1021/ci100436p · DOI · Paper page
  50. RA Carr, 2005, Fragment-based lead discovery: leads by design, Drug Discov Today, 10, 987, 10.1016/S1359-6446(05)03511-7 · DOI · Paper page
  51. A Broer, 1999, The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux, J Neurochem, 73, 2184, 10.1046/j.1471-4159.1999.02184.x · DOI · Paper page
  52. N Watzke, 2001, Early intermediates in the transport cycle of the neuronal excitatory amino acid carrier EAAC1, J Gen Physiol, 117, 547, 10.1085/jgp.117.6.547 · DOI
  53. Q Wang, 2011, Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression, Cancer Res, 71, 7525, 10.1158/0008-5472.CAN-11-1821 · DOI · Paper page

Cited by

Metadata

Authors
Colas, C., Grewer, C., Otte, N. J., Gameiro, A., Albers, T., Singh, K., Shere, H., Bonomi, M., Holst, J., & Schlessinger, A.
Venue
PLOS Computational Biology
Published
2015-10-07
Volume
11
Issue
10
Pages
e1004477
ISSN
  • 1553-734X (ISSN-L)
  • 1553-7358
OpenAlex
W1832385088
Cited by
67
References
8
FWCI
3.88
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.